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Unconjugated hyperbilirubinemia is a common condition in the ﬁrst week of postnatal life.
Although generally harmless, some neonatesmay develop very high levels of unconjugated
bilirubin (UCB), which may surpass the protective mechanisms of the brain in preventing
UCB accumulation. In this case, both short-term and long-termneurodevelopmental disabil-
ities, such as acute and chronic UCB encephalopathy, known as kernicterus, or more subtle
alterations deﬁned as bilirubin-induced neurological dysfunction (BIND) may be produced.
There is a tremendous variability in babies’ vulnerability toward UCB for reasons not yet
explained, but preterm birth, sepsis, hypoxia, and hemolytic disease are comprised as risk
factors. Therefore, UCB levels and neurological abnormalities are not strictly correlated.
Even nowadays, the mechanisms of UCB neurotoxicity are still unclear, as are speciﬁc
biomarkers, and little is known about lasting sequelae attributable to hyperbilirubinemia.
On autopsy, UCB was shown to be within neurons, neuronal processes, and microglia,
and to produce loss of neurons, demyelination, and gliosis. In isolated cell cultures, UCB
was shown to impair neuronal arborization and to induce the release of pro-inﬂammatory
cytokines from microglia and astrocytes. However, cell dependent sensitivity to UCB toxi-
city and the role of each nerve cell type remains not fully understood.This review provides
a comprehensive insight into cell susceptibilities and molecular targets of UCB in neurons,
astrocytes, and oligodendrocytes, and on phenotypic and functional responses of microglia
to UCB. Interplay among glia elements and cross-talk with neurons, with a special empha-
sis in theUCB-induced immunostimulation, and the role of sepsis in BIND pathogenesis are
highlighted. New and interesting data on the anti-inﬂammatory and antioxidant activities
of different pharmacological agents are also presented, as novel and promising additional
therapeutic approaches to BIND.
Keywords: unconjugated hyperbilirubinemia, neurotoxicity, reactive astrocytes, activated microglia, sepsis, pro-
inflammatory cytokines, oxidative stress, myelin
INTRODUCTION
Jaundice occurs during the ﬁrst week of life in most infants due
to elevated levels of unconjugated bilirubin (UCB) by increased
breakdown of fetal erythrocytes, deﬁcient human serum albu-
min (HSA) transport to the liver, and inefﬁcient conjugation.
Although the outcome for the majority is benign, untreated
neonates, or newborns with very high UCB levels can develop
acute encephalopathy or kernicterus. The most disabling neuro-
logical ﬁndings in kernicterus are auditory and motor sequelae.
At autopsy of kernicteric infants, UCB is macroscopically visi-
ble within globus pallidus, hippocampus, lateral ventricular walls,
cerebellum, and subthalamic nuclei, reﬂecting a preferential depo-
sition of UCB in speciﬁc brain areas. Unfortunately, no established
criteria recognize whether neurological or developmental prob-
lems result fromhyperbilirubinemia.Nevertheless, patient history,
physical examination, and laboratory ﬁndings allow the catego-
rization of kernicterus as mild, moderate, or severe. Recently,
Shapiro (2010) has suggested the term of subtle kernicterus for the
less severe injuries, including minor neurological abnormalities.
This milder form of bilirubin induced neurological dysfunc-
tion (BIND) in the central nervous system (CNS) needs to be
distinguished from other known causes of neurodevelopmental
disabilities. Further studies looking at potential alterations pro-
duced by UCB on neurodevelopmental programs and lasting
neurological deﬁcits that may involve vulnerability to aging and
neurodegenerative diseases are needed.
To reduce BIND incidence, normograms, and guidelines were
proposed (Bhutani et al., 2008) for jaundiced newborn infants
of 35 or more weeks of gestation. However, in sick and preterm
infants, the absence of precise data on hyperbilirubinemia preva-
lence and the lack of proven predictive indices has made impos-
sible to establish such guidelines. Therefore, the problem is even
more worrying for premature babies and low birth weight infants,
mainly when infection/sepsis is associated, but also because
they are particularly vulnerable to BIND (Bhutani et al., 2004;
Okumura et al., 2009; Moll et al., 2011), probably due to neu-
rodevelopmental maturity differences. In fact, temporal windows
of CNS vulnerability to UCB toxicity have been suggested and
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the neurodevelopmental age at the time of UCB brain injury
inﬂuences the location of the selective neuropathological damage
(Keino and Kashiwamata, 1989; Conlee and Shapiro, 1997). While
auditory predominant kernicterus subtype prevails in infants with
peak levels at earlier gestational ages of exposure to total serum
bilirubin (TSB), motor kernicterus subtype usually develops in
infants with more than 34weeks of gestation (Shapiro, 2010).
TSB is the sum of UCB plus the fraction of the pigment that
has already been conjugated in the liver. Interestingly, if we look
into two different mice models with equivalent TSB levels, results
indicate that when hyperbilirubinemia develops in the ﬁrst week
of life, such as in the Ugt1−/− model (Nguyen et al., 2008), all the
animals succumb, while if occurring in the second week of life
as in the Tg(UGT1A1∗28)Ugt1−/− model (Fujiwara et al., 2010),
only 10% of the mice dye. These ﬁndings suggest an acquired
resistance with the postnatal age. Therefore, high levels of UCB
during early neurodevelopment may determine injuries that can
be diverse in nature, severity, and enduring effects from those
produced a week later.
Neonatal jaundice, if prolonged or severe, could have an impact
on the infant’s learning and memory, and even moderate levels of
UCB have been associated with developmental delay, attention-
deﬁcit disorder, autism,and isolatedneural hearing loss (Gkoltsiou
et al., 2008; Jangaard et al., 2008; Shapiro, 2010). However, the
establishment of these casual relationships was never demon-
strated with certainty because of the two decades that separate
neonatal jaundice fromsigns of mental disorders at puberty.More-
over, neonatal hyperbilirubinemia,mainly in prematures, could be
one of themultifactorial risk factors leading to long-lasting deﬁcits
as recently evidenced formoderate systemic inﬂammation (Favrais
et al., 2011). Thus, elucidation of structural–functional relation-
ship might help in understanding the pathological processes and
developmental difﬁculties experienced by jaundiced babies.
In vitro experiments have been elucidating the mechanisms of
UCB neurotoxicity (Brites et al., 2009; Brites, 2011), while in vivo
studies have almost exclusively focused on homozygous (jj) Gunn
rats (Rice and Shapiro, 2008; Daood et al., 2009), the kernicterus
classic model. Hyperbilirubinemic Gunn rats have a congenital
deﬁciency of the bilirubin liver conjugating enzyme uridine-
diphosphate-glucuronosyltransferase 1A1 (UGT1A1) and present
neurological abnormalities similar to kernicterus (Billing, 1972)
when acute bilirubin encephalopathy is induced by the admin-
istration of phenylhydrazine (Rice and Shapiro, 2008) or sul-
fadimethoxine (Daood et al., 2009). Indeed the model, although
indicated as mimicking the Crigler–Najjar I syndrome due to a
defect in the UGT1A1 isoform of the UDPGT gene (Johnson
et al., 1959), evidence less severe hyperbilirubinemia, and the
natural course of the disease is milder in the Gunn rat than
in human Crigler–Najjar I syndrome (Shapiro, 2003). Interest-
ingly, Gunn rats with mild concentrations of UCB at 2months
of age (∼3mg/dL) have exhibited behavioral alterations and neu-
ropathological changes similar to those found in schizophrenia
(Hayashida et al., 2009).
Hence, clariﬁcation of the molecular mechanisms of UCB neu-
rotoxicity is an emerging area of research as it may open new
perspectives for therapeutic approaches at circumventing poten-
tial enduring injurious effects of neonatal brain insults by UCB.
The aim of this review is to highlight the most recent and rele-
vant information on the determinants and widespread effects of
UCB neurotoxicity, the potential molecular mechanisms involved
and the associated neurodevelopmental susceptibilities, as well as
the glia immune-inﬂammatory responses and the most promis-
ing neuropharmacological agents based on in vitro experimental
models.
DETERMINANTS OF BRAIN BILIRUBIN ENTRANCE AND
LOAD
Several factors in the ﬁrst week of postnatal life may concur to
increase the amount of UCB in the circulation, which when sur-
passing the albumin-binding capacity for UCB lead to an increase
of the unbound (free) fraction of UCB (Bf). Although UCB
entrance into the brain is prevented by the brain microvascular
endothelial cells tightly jointed by the elaborated junctional com-
plexes that form the blood–brain barrier (BBB; Cardoso et al.,
2010; Figure 1A), Bf diffuses into the brain (Ostrow et al., 2003b),
and its accumulation in the CNS will depend on the total amount
of Bf in the systemic circulation, on the efﬁcacy of BBB trans-
porters, and on the presence of acidosis, which increases binding
of Bf to the brain parenchyma and the risk of kernicterus (Cashore
et al., 1983; Meisel et al., 1988), due to its decreased solubility in
acidic aqueous solutions (less than 1 nM at pH= 7 and about
0.1μM at pH= 8; Ostrow and Celic, 1984).
ATP-dependent cellular export of UCBby P-glycoprotein (Pgp)
and multidrug resistance-associated protein 1 (MRP1/Mrp1),
which are highly expressed in BBB and inCSF (Gazzin et al., 2011),
respectively, limit Bf passage across the BBB (the ﬁrst one) and
its intracellular accumulation (mainly the last one; Sequeira et al.,
2007; Daood et al., 2008; Bellarosa et al., 2009). However, the lower
expression of Pgp in early-life (Daood et al., 2008; Gazzin et al.,
2011) may be critical in preventing UCB entrance into the CNS.
Similarly,Mrp1 down regulation by long exposure to elevated con-
centrations of UCB, recently observed at the blood–CSF barrier
in the Gunn rats, might favor BIND (Gazzin et al., 2011). UCB
can even compromise the integrity of BBB lining by disrupting
glutathione (GSH) homeostasis and increasing endothelial nitric
oxide synthase (NOS) expression followed by nitrite (NO) pro-
duction and cytokine release (Palmela et al., 2011), thus favoring
UCBbrain uptake in prolonged hyperbilirubinemia. Formation of
NO, originally described as the endothelial-derived relaxing factor
(Bellefontaine et al., 2011), requires NOS, in which there are three
isoforms: two constitutive (i) neural-type NOS I (nNOS) and (ii)
endothelial-type III (eNOS), and one inducible NOS II (iNOS)
isoform. Interestingly, upregulation of eNOS expression was more
pronounced in the ﬁrst 4 h incubation and showed to increase
with the concentration of UCB (Palmela et al., 2011). The elevated
levels of NO generated may increase microvascular permeability
(Kim and Jung, 2011), thus favoring passage of UCB into the brain.
Once in the brain, preferential deposition and neurotoxicity of
UCBmay result fromcell speciﬁc susceptibilities andCNS regional
vulnerabilities, while time of exposure will be critical in extend-
ing UCB load and toxicity (Wennberg et al., 2006). Localization
of Mrp1 in astrocytes and of Pgp in those associated to BBB may
help in restricting UCB injury to cells located at BBB proxim-
ity and to maintain BBB properties in mild hyperbilirubinemia
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FIGURE 1 | Schematic of the blood–brain barrier (BBB) in a condition of
mild hyperbilirubinemia (A) and overview of the mechanisms that
prevent the accumulation of unconjugated bilirubin (UCB) in astrocytes
(B). (A)The normally functioning BBB maintains the central nervous system
homeostasis by separating the brain from the systemic blood circulation and
regulating the exchange of various compounds. The BBB is composed by
endothelial cells (orange) and their tight junctions (TJ), located more apically,
and adherens junctions (AJ), located underneath, as well as by astrocyte
end-feet (light blue spots), perivascular microglia (greenish-brown), pericytes
(light-green), and the basement membrane (yellow). Integrity of all BBB
elements is essential for neuron (pink) function and for oligodendrocytes
(solid-green) to exert protection of axon function and promotion of neuronal
survival. Circulation of UCB in the blood is provided by its binding to human
serum albumin. Thus, decreased levels of albumin, the lower capacity for UCB
binding, and the high UCB concentrations favor the entrance of unbound
(free) UCB (Bf) fraction by passive or facilitated diffusion into the brain. In a
condition of mild hyperbilirubinemia the Bf levels in the plasma rarely surpass
100 nM and in the brain are usually lower than 10 nM; entrance restriction to
UCB is afforded by the P-glycoprotein (Pgp) at the BBB, which is an
ATP-dependent cellular export protein of UCB. (B) At the brain cells, UCB is a
substrate for the efﬂux pump multidrug resistance-associated protein 1
(Mrp1) and together with Pgp limit the intracellular accumulation of UCB,
mainly in astrocytes. Reduced expression of Pgp and Mrp1 in young
astrocytes and neurons, as well as in Gunn rats’ pups, probably account to
the vulnerability of premature babies to UCB. A high intracellular
concentration of glutathione (GSH) protects against reactive oxygen species
(ROS). GSH is regenerated from glutathione disulﬁde (GSSG) in a reaction
catalyzed by glutathione reductase (GR) using NADPH as a second substrate.
Astrocytes release GSSG under oxidative stress via Mrp1. Another protective
mechanism against UCB toxicity is the mitochondrial membrane enzyme
bilirubin oxidase which in the presence of molecular oxygen converts UCB to
biliverdin (BV) and other products that are much less toxic than UCB. Changes
in BBB integrity will lead to UCB entrance into the brain, and failure of cell
defensive mechanisms against UCB toxicity will favor brain injury.
(Watchko et al., 2001). Rigato et al. (2004) have demonstrated that
Mrp1 mediates ATP-dependent cellular export of UCB by astro-
cytes (Figure 1B). GSH protects astrocytes from reactive oxygen
species (ROS) by directly reacting with radicals and by reduc-
ing peroxides generating oxidized glutathione (GSSG). In order
to maintain a reduced thiol reduction potential under oxidative
stress, Mrp1 mediates GSSG release from astrocytes (Hirrlinger
et al., 2001). Mrp1 expression was also shown in neurons (Falcão
et al., 2007a). Moreover, it was observed that immature neurons
and astrocytes exhibit low levels of the protein as compared with
mature cells, in line with what was observed for Pgp, and that inhi-
bition of Mrp1 expression with MK571 increases UCB toxicity to
neurons and astrocytes (Falcão et al., 2007a), as well as to human
neuroblastoma SH-SY5Y cells when RNA interference technology
was used (Corich et al., 2009).
Another important defense mechanism resides on the ability of
UCB oxidation by brain mitochondrial membranes (Figure 1B),
at a rate of 100–300 pM UCB/mg protein/min (Hansen, 2000a).
The enzyme activity showed to be cytochrome c dependent, but
it is not inﬂuenced either by GSH or GSSG (Hansen et al., 1999).
Once it is less expressed in immature brains, as well as in undif-
ferentiated cells, and in neurons than in glia (Hansen and Allen,
1997), it is hypothesized that it could be related to the increased
vulnerability of the newborn to UCB, mainly if premature.
Microscopic evaluation of icteric stained brain sections
revealed that UCB interacts with neurons, neuronal processes, and
glia elements (Martich-Kriss et al., 1995), but the contribution of
each cell type to BIND is not clear, mainly when considering the
UCB-induced nerve cell pathological alterations as an integrated
phenomena, i.e., by using organotypic slice cultures. If neurons
are highly specialized for the processing and transmission of cel-
lular signals, glial cells, which include astrocytes, microglia, and
oligodendrocytes (OLGs), are essential in the maintenance of the
neuronal network, in neuronalmigration during development and
in the generation of myelin, respectively. Therefore, once such
cells are important players in neuronal dysfunction they should
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be considered as promising therapeutic targets in BIND. More-
over, one must consider glial damage not as a marginal event
or a secondary consequence of neuronal injury, but rather as
an intrinsic participant and determinant of the UCB-induced
neuropathological processes.
BIOMARKERS AND PREDICTORS OF BILIRUBIN
NEUROTOXICITY
Classical and subtypes of kernicterus associated with kernicterus
and BIND, respectively, have been related to auditory impair-
ment (Shapiro and Popelka, 2011). Intriguingly, it was observed
that from a total of 13 neonates with severe hyperbilirubinemia,
six infants had audiologic ﬁndings of acute auditory neuropa-
thy spectrum disorder, while only two from the six had clini-
cal signs and symptoms of acute UCB encephalopathy (Saluja
et al., 2010). Therefore, abnormal neurological function with
auditory brainstem responses (ABRs), also known as brainstem
auditory evoked potentials (BAEPs), or responses (BAERs), is con-
sidered a very objective and sensitive test for the diagnosis of
kernicterus and UCB neurotoxicity, once these auditory regions
are too small to be seen on conventional magnetic resonance
imaging (MRI) scans (Gupta and Mann, 1998; Shapiro, 2010).
Actually, audiological diagnostic work-up in neonatal hyperbiliru-
binemia above 20mg/dL, and even for UCB at <20mg/dL, has
been recommended (Sheykholeslami and Kaga, 2000; Nickisch
et al., 2009).
Aberrant ABRs have been consistently used as a non-invasive
method to identify UCB toxicity in Gunn rats. However, UCB by
itself is not able to cause hearing impairment in jaundiced Gunn
rats (Levi et al., 1981), unless combined with induced asphyxia
(Silver et al., 1995a). Other sensitive markers for the massive entry
of UCB into the nervous system include the somatosensory evoked
potential (Silver et al., 1996) and visual evoked potential abnor-
malities (Silver et al., 1995b), both observed in the Gunn rats, in
the absence or in the presence of sulfadimethoxine, respectively.
Nevertheless, in what concerns biomarkers to evaluate the risk
of BIND,Bf is considered a more sensitive predictor (Ahlfors et al.,
2009b; Lee et al., 2009) than either bilirubin–albumin molar ratio
(UCB/HSA) or abnormal ABR maturation (Amin et al., 2001)
and, in contrast to TSB levels, revealed to be associated with ABRs
results (Ahlfors and Parker, 2008). In sum, Bf or TSB plus Bf,
instead of TSB alone, aremore rational indicators (Wennberg et al.,
2006). However, due to the difﬁculties of Bf assessment in the clin-
ical practice it has been referred the use of TSB/HSA instead of
UCB alone (Hulzebos et al., 2008). Additionally, the HSA (Ahlfors
et al., 2009a) and the “reserve HSA binding capacity” (McDon-
agh, 2010) determinations are indicated as complementary, and
a Bf of 20 nM proposed as the risk threshold for UCB toxicity
in term infants (Wennberg et al., 2006). In fact, while the val-
ues of TSB only varied between 116 and 615 μM in infants with
birth weight higher or equal to 2.5 kg, greater variations in Bf con-
centrations (from 0.9 to 130 nM) were encountered, reinforcing
the need of individualized jaundice management (Ahlfors et al.,
2009b). Finally, the Bf/TSB ratio is even believed to be a best dis-
player of abnormal BAEPs than Bf alone (Ahlfors et al., 2009a).
However, when the challenge resides in relating Bf or TSB with
abnormal neurodevelopmental and lasting neurological changes,
alterations in ABRs are considered the top clinical approach.
Recently, it was suggested that serum tau and S100B protein
levels are equally promising biomarkers, which besides being cor-
related with TSB, were found to be more elevated in infants with
auditory neuropathy, neurologic defects, or electroencephalo-
gram abnormalities (Okumus et al., 2008), and consequently with
UCB-induced brain sequelae.
HOW DOES BILIRUBIN MAKE NEURONS SICK?
Most published studies on the neurotoxicity of UCB have been
performed either at too high UCB/HSA molar ratio (>3) or at
UCB values in the absence of serum or albumin, Bf, vastly higher
(>1μM) than those seen in jaundiced neonates at risk of ker-
nicterus or BIND (between 100 and 500 nM), and thus are of
questionable relevance to the clinical manifestations of neurotox-
icity (Ostrow et al., 2003a). In fact, those Bf concentrations in
the absence of HSA form microsuspensions, followed by coarser
aggregates that precipitate spontaneously,mainly at the level of the
cellular membranes. Some data suggest that metastable aggregates
begin to occur at concentrations of Bf as low as 1–2μM and prob-
ably not at 500 nM (Mukerjee et al., 2002; Ostrow et al., 2003a).
Once bilirubin has been referred as a neuroprotective compound,
as well, it deserves to be noted that only Bf concentrations below
100 nM are able to protect CNS against oxidative damage (Doré et
al., 1999; Dora Brites lab, unpublished results). Therefore, we have
privileged in this section the studies addressing the neurotoxic
effects produced by moderately supersaturated Bf levels (between
100 nM and 1μM) and/or UCB/HSA molar ratios ≤3.
Neurons are more susceptible than astrocytes to UCB-induced
demise, probably as a result of lower GSH content (Brito et al.,
2008b). Indeed, neurons generally show higher levels of ROS, pro-
tein oxidation, and lipid peroxidation upon UCB exposure than
astrocytes, despite the different vulnerability of neuronal subpop-
ulations (Conforti et al., 2007). One of the most challenging issues
is to deﬁne the earliest steps of injury once it can differ on time,
severity, and site between one cell and another (Muramatsu et al.,
2009).Years ago,Chen et al. (1971) suggested, based in their exper-
imental kernicterus model, that after absorption of UCB from
astrocytes at the dendritic level, UCB is transported from the dis-
torted microtubules to the Golgi complex, before the enlarged
vesicles coming from the Golgi reach the granular endoplasmic
reticulum (ER), which in turn show vesiculation, vacuolation, and
dilated cisternae.
Interaction of UCB with the cells occurs ﬁrst at the cell
membrane (Figure 2A), and although UCB rapidly diffuses
through membranes (Zucker et al., 1999), it was shown that it
causes increased polarity and ﬂuidity at carbon numbers 5 and
7 (Rodrigues et al., 2002c), ultimately perturbing the neuronal
cell membrane structure. These features showed to be associated
with oxidative injury to membrane lipids and were not sensed
in the more hydrophobic regions. Similar effects were observed
on membranes of astrocytes (Rodrigues et al., 2002c) and ery-
throcytes (Brito et al., 2001), as well as on mitochondrial mem-
brane (Rodrigues et al., 2002b). This increased membrane ﬂuidity
favors the externalizationof phosphatidylserine to the outer leaﬂet,
which allows phagocytic recognition. This ﬁnding, also observed
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FIGURE 2 | Model of UCB interaction with neural plasma membrane
(A) and pathways by which UCB may affect neuronal function (B). Cell
membrane includes a bilayer of packed phospholipids, cholesterol, and
integral proteins. (A)The inset represents a phospholipid of the outer
membrane containing a phosphatidyl-glycerol polar (hydrophilic head) and two
fatty acids (hydrophobic tails). The phosphate group is attached to the glycerol
and form ester links with a variety of other molecules. UCB decreases
phospholipid mobility and the polarity at carbon (C) 5, while increased it at C7,
and less markedly at C12 and C16 (orange). The intercalation at C5 may trigger
the release of phospholipids and cholesterol, as well as the externalization of
the phosphatidylserine, a recognition signal for phagocytosis. (B)
UCB-induced protein oxidation and lipid peroxidation may arise from increased
reactive oxygen species (ROS) production. UCB impairs Mg2+-ATPase activity,
responsible for the maintenance of phosphatidylserine in the inner leaﬂet, and
Na+, K+-ATPase, which may trigger the intracellular intrusion of calcium (Ca2+).
Opening of Ca2+channels, as well as the activation of NMDA receptors by
UCB, recognized to modulate the exocytosis of glutamate, can also account
to it. Changes in membrane polarity and ﬂuidity, equally produced at the
mitochondrial membrane by UCB, lead to the collapse in the mitochondrial
transmembrane potential (ΔΨm), translocation of proapoptic Bax to the
mitochondria, inhibition of cytochrome c oxidase activity (complex IV of the
respiratory chain), and efﬂux of cytochrome c. Then, activation of caspases 3
and 9 (intrinsic apoptotic cascade) takes place, as well as UCB-induced
(Continued)
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FIGURE 2 | Continued
activation of caspase-8 (extrinsic apoptotic cascade) and the cleavage of
Bid into truncated Bid (tBid). Oxidation of GSH to GSSG and inability to be
restored is associated with the increased ROS generation, which may
determine DNA damage. DJ-1 that is early up-regulated, to diminish
UCB-induced oxidative stress, is latter on oxidized and proteolitically
degraded due to the reduced levels of GSH. Increased superoxide anion
radical production (O•−2 ) and decreased NADPH upon exposure to UCB
also account to the oxidative stress. Glycolysis upregulation by UCB lead
to increased intracellular lactate content and inhibition of the pentose
phosphate pathway (PPP), providing ATP to support the bioenergetic crisis.
UCB-asscociated nitrosative stress derives from the increased expression
of nNOS and generation of NO and cyclic guanosine 3′,5′-monophosphate
(cGMP). Actually, NO signaling, c-Jun N-terminal kinases (JNK1/2)
stimulation, activation of nuclear factor-kappaB (NF-κB) with translocation
to the nucleus, ROS generation, and activation of caspases are key players
in the induction of genes involved in UCB-induced neuronal demise by
necrosis and apoptosis.
in erythrocyte membranes (Brito et al., 2002) and synaptosomes
(Brito et al., 2004) after exposure to UCB, was accompanied by
reduced activities of Mg2+-ATPase aminophospholipid translo-
case (ﬂippase) and Na+, K+-ATPase, together with enhanced
intracellular levels of calcium (Ca2+; Figure 2B). These effects
can lead to cell destruction, as evidenced by the hemolysis of
erythrocytes (Brites et al., 1997; Khan and Poduval, 2011). Ca2+
inﬂux or increased release of Ca2+ from ER or other stores may
contribute to the intracellular increase of Ca2+. However, Zhang
et al. (2010) demonstrated that UCB mainly induces the open-
ing of the Ca2+ channel. Ca2+ inﬂux into cortical neurons was
shown to regulate the expression of nNOS mediated by a cAMP
response element-binding (CREB) family transcription factor-
dependent mechanism (Sasaki et al., 2000). Later it was shown
that UCB-induced phosphorylation of CREB, induction of nNOS,
and generation of NO,was indeed dependent of extracellular Ca2+
(Mancuso et al., 2008). Both extracellular signal regulated kinases
(ERK1/2) (Mancuso et al., 2008) and c-Jun N-terminal kinases
(JNK1/2) (Vaz et al., 2011b) phosphorylation is mediated through
the NOS/NO pathway, but at least ERK activation seems to not
depend from extracellular Ca2+ (Mancuso et al., 2008).
Developing neurons are particularly susceptible to UCB inter-
action which causes neurogenesis impairment, neuritic atrophy,
and cell death by both necrosis and apoptosis (Figures 3A,B; Brito
et al., 2002; Falcão et al., 2007c) that is enhanced by associated
hypoxia (Vert et al., 2001). Impact results in sudden and lasting
decrease in neuronal arborization, as well as in reduced num-
ber of dendritic spines and synapses (Fernandes et al., 2009b),
and cells stayed sensitized and increasingly vulnerable to a sec-
ondary toxic stimulus (Falcão et al., 2007c). The observed neurite
outgrowth impairment is consistent with UCB-induced neurode-
velopmental abnormalities, by interfering with neural plasticity,
and hippocampal susceptibility corroborates the brain regional
speciﬁcity toward UCB in bilirubin encephalopathy (Jangaard
et al., 2008). It deserves to be noted that even in more differenti-
ated neurons (10 days in vitro) impairment in neurite outgrowth
by UCB is still observed after 12–24 h of exposure (Zhang et al.,
2010). However, it was reported that cells are able to reverse some
of theUCB-mediated effects when it is used a shorter (6 h), instead
of a longer exposure time (12 or 24 h; Hankø et al., 2006b).
Alterations of UCB at neuronal arborization derive, at least in
part, from cytoskeleton changes elicited in microtubule associated
proteins (MAP) in immature neurons. Extended MAP2 entry in
the axonal shaft (Figures 4A,B) and increased Tau1 expression
by UCB, promotes Tau1 binding to microtubules and its release
into the cytoplasm (Fernandes et al., 2009a, 2010; Figures 4C,D).
Tau is localized in the axon and MAP2 is somato-dendritically
compartmentalized. Mislocalization of Tau to dendritic spines
and subsequent synaptic impairment appears to precede neuronal
loss (Hoover et al., 2010) and its release into the extracellular
space, from where it can reach the CSF and the plasma (Qiang
et al., 2006). Therefore, the increased Tau levels observed in serum
are considered to be a predictive indicator of neurodegeneration
(Wang and Liu, 2008; Noguchi-Shinohara et al., 2011) and Oku-
mus et al. (2008) have proposed that it should be considered
a biomarker of BIND. Further studies should elucidate on this
and other promising biomarkers of early neuronal dysfunction
by UCB, as well as on the temporal window of reversibility, so
that clinical detection and rescue intervention treatments can be
achieved.
In addition, UCB also causes synaptotoxicity that has been
related with potentiation of inhibitory synaptic transmission (Shi
et al., 2006), as well as with impairment of the induction of long-
term potentiation (LTP) and long-term depression (LTD; Chang
et al., 2009). Interestingly, UCB was shown to decrease the expres-
sion of synaptophysin and SNAP-25 (Silva et al., 2012), proteins
that participate in synapse establishment and neurotransmitter
release (Wang and Tang, 2006). Accordingly, UCB was demon-
strated to cause presynaptic degeneration in the Gunn rat, while
preserving postsynaptic neurons (Haustein et al., 2010).
Mitochondria swelling by UCB (Solá et al., 2002), as well
as Bax translocation, mitochondrial depolarization, release of
cytochrome c, activation of caspase-3, and degradation of
poly(ADP)ribose polymerase (Rodrigues et al., 2002a)were shown
to be implicated in neuronal apoptosis by UCB (Figure 2B). Inhi-
bition of cytochrome c oxidase in mitochondria isolated from
mice brain (Malik et al., 2010) and in immature cortical neu-
rons obtained from rats, in which UCB evidenced to affect cell
respiration due to the low oxygen consumption, account for the
decrease in mitochondrial functional activity by UCB (Vaz et al.,
2010). In addition, while low and moderate concentrations of
UCB may favor a delayed apoptosis in cultured human NT2-
N neurons, moderate and high levels preferentially trigger early
necrosis (Hankø et al., 2005). Cell death prevalence in immature
(3–4 days in vitro) neurons, mostly by apoptosis (Falcão et al.,
2006; Figure 3B), involves a bioenergetic and oxidative crisis (Vaz
et al., 2010). Oxidative stress derives from the increased superox-
ide anion radical production (O•−2 ) (Figure 2B) together with an
elevation of the GSSG relatively to the total glutathione (GSH plus
two times GSSG), as well as from a decrease in NADPH concentra-
tion. It is conceivable that the upregulation of glycolysis by UCB
will be an attempt to provide ATP to support the bioenergetic
crisis, while ATP release resulting from the NO production and
oxidative stress should be associated with apoptosis.
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FIGURE 3 | Effects of unconjugated bilirubin (UCB) are
concentration-dependent, more pronounced in astrocytes (Ast) than
in neurons (Neu), and most sensed by undifferentiated (young) cells,
which also show increased demise by co-incubation with
lipopolysaccharide (LPS).To mimic young (immature), mature, and old
cells, and to achieve the same stage of differentiation in both, rat cortical
astrocytes and neurons were cultured for 5, 10, and 20 days in vitro (DIV)
or 4, 8, and 18 DIV, respectively. Cells were incubated with 50 or 100μM
puriﬁed UCB, or no addition (control), in the presence of 100μM human
serum albumin, at pH 7.4, for 4 h, at 37˚C. In sister experiments, cells were
co-incubated with 1 ng/L LPS and results were expressed as fold LPS
induction. (A) Results of lactate dehydrogenase (LDH) release by
non-viable cells are expressed as percentage of cell death relatively to
total cell lysis. Astrocytes are the most susceptible cells, and LPS effects
are similarly produced in both type of cells, although mature astrocytes are
the most vulnerable. (B) Apoptosis was estimated by analysis of nuclear
morphology following staining with Hoechst 33258 dye. Immature and
mature cells reveal enhanced vulnerability to UCB and old astrocytes
greater apoptosis by associated LPS. (C) Release of glutamate to the
incubation medium proportionally increases with UCB concentration and it
is not modiﬁed by LPS co-incubation. (D)The pro-inﬂammatory cytokine
tumor necrosis factor (TNF)-α is released to the culture medium mainly by
astrocytes and always increase by LPS addition. Mean values±SEM are
differences from the respective control, for all the parameters except for
the fold increase by LPS, which data are means. Data derived from
Fernandes et al. (2004) and Falcão et al. (2005, 2006, 2007c).
The N -methyl-d-aspartate (NMDA) receptor-mediated exci-
totoxic mechanism is another pathway leading to UCB-induced
neuronal injury, providing the necessary increase in intracellu-
lar Ca2+ required for activation of nNOS (Bellefontaine et al.,
2011). In fact, UCB was demonstrated to raise the extracellular
concentration of glutamate, by enhancing its release mainly from
immature neurons (Falcão et al., 2006; Figures 2B and 3C), thus
engendering overstimulation of NMDA receptors (Ostrow et al.,
2004; Falcão et al., 2006; Brites et al., 2009). In addition, pro-
longed UCB exposure led to a decrease in presynaptic transmitter
release but also impaired the postsynaptic NMDA receptor func-
tion (Chang et al., 2009). Therefore, the use of NMDA receptor
antagonist MK-801 was shown to prevent the expression of nNOS,
the consequent release of NO, the production of cyclic guano-
sine 3′,5′-monophosphate (cGMP), as well as cell dysfunction and
demise (Hankø et al., 2006a; Brito et al., 2010), but not the extra-
cellular accumulation of glutamate in primary cultures of cortical
neurons (Brito et al., 2010). Conﬂicting results were observed for
MK-801 in hippocampal neurons treated with high UCB levels
(Shapiro et al., 2007), not considered clinically relevant by sur-
passing UCB aqueous solubility (Ostrow et al., 2003b; Zhou et al.,
2010), and in Gunn rats pups, where no protection against BAEPs
abnormalities was observed (Shapiro et al., 2007).
Increased expression of nNOS by upregulation at both the
mRNA and the protein level and the generation of NO were
shown to depend from neurotrophins (Mancuso et al., 2008).
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FIGURE 4 | Exposure of immature hippocampal neurons to
unconjugated bilirubin (UCB) impairs neuronal arborization by
reducing axonal ramification and dendritic output, while increasing
microtubule stability by changing the expression and localization
patterns of the microtubule (MT) associated protein 2 (MAP2) and
Tau1. Embryonic hippocampal neurons were treated with vehicle (human
serum albumin, HSA) alone (control) or with UCB 100μM (UCB/HSA=1)
for 24 h at 1 day in vitro (DIV) and ﬁxed at 3 DIV. Representative images of
hippocampal neurons immunostained with MAP2 (green) to identify the
cell body and dendrites, andTau1 (red) to identify the axon, are shown in
(A) for control and (B) for UCB. UCB induces MAP2 axonal entry,
evidenced by the white arrowheads pointing to the portion of axon with
MAP2 entry, and a decrease in the number of axonal and dendritic
branches when compared with HSA alone. Graph bars representing
total and MT-boundTau1 are shown in (C) illustrating that UCB induces
axonal expression of Tau1. Percentage of Rel-Tau1 and MT-Tau1 in the pie
chart in (D) depicts that part of Tau1 will be increasingly bound to
microtubules (MT-Tau) (C,D), although the major portion is released
(Rel-Tau), as illustrated in (D). Data derived from Fernandes et al. (2009a,
2010).
These Authors have shown that 10μM Bf reduces the forma-
tion of H2O2-induced ROS, contributing to the inhibition of the
nerve growth factor and the brain-derived neurotrophic factor
signaling to Akt and ERK1/2 decreased phosphorylation. Intrigu-
ingly, in the absence of endogenous growth factors,UCBevidenced
to activate an NO-dependent cascade leading to ERK activation,
actions that the same Authors hypothesize to result from cell
membrane perturbation and calcium inﬂux in PC12 cells. There-
fore, UCB neurotoxicity would derive in the perspective of these
Authors from thepresence of neurotrophinswhichpredominate in
hippocampus and cerebellum on the perinatal life in order to pro-
mote neuronal development and differentiation. Recently, it was
observed an increased expression of nNOS by UCB in hippocam-
pal neurons, as compared to cerebellar or cortical neurons (Vaz
et al., 2011a), indicating a particular susceptibility of hippocampus
to nitrosative stress. Most important, acute hyperbilirubinemia by
administration of sulfadimethoxine to theGunn rat was evidenced
to lead to a presynaptic failure of synaptic transmission, consid-
ered to be in the basis of UCB-induced deafness and related to the
upregulation of nNOS and generation of NO. In fact, the admin-
istration of a nNOS antagonist has shown to protect the loss of
auditory function (Haustein et al., 2010), highlighting the role
of NO in the neurotoxic mechanisms of UCB. Additional studies
are necessary to further explore the UCB-dependent neurotoxic-
ity from growth factor availability, as proposed by Mancuso et al.
(2008).
Both glutamate (Silva et al., 2012) and oxidative stress (Vaz
et al., 2011a) were shown to mediate the disruption of neuronal
dynamics by UCB. Interestingly this effect, similarly to nNOS
induction, was also more evident in neurons from the hippocam-
pus than in those from the cortex and the cerebellum. To that
should account the decreased levels of DJ-1, a protein with a
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protective role against oxidative damage (Lev et al., 2008; Kahle
et al., 2009), the increased nitrosative stress, ROS production and
GSSG evidenced by hippocampal neurons when treated with UCB
(Vaz et al., 2011a). Similarly to other studies pointing to DJ-1 over-
expression as a mechanism to protect cells from UCB-induced cell
death (Deganuto et al., 2010), our data also evidenced an early
upregulation effect (Vaz et al., 2011a), probably as an initial effort
to diminish UCB-induced oxidative stress. However, in this last
study it only lasted 4 h instead of the 24 h observed by Deganuto
et al. (2010). These different results may be caused by the use of
different models, in the case the human neuroblastoma cell line
SH-SY5Y and not hippocampal neurons from Wistar rats as we
used. The low levels of DJ-1 later observed (24 h) may result from
its oxidation due to the decreased levels of GSH (Miyama et al.,
2011) and degradation through proteolysis (Saeed et al., 2010).
Inability to restore GSH from GSSG is related to the increased
production of ROS and oxidative damage of proteins and lipids
(green broken line, Figure 2), leading to DNA damage (Wiseman
and Halliwell, 1996), which was evidenced to be produced by UCB
in the neuroblastoma cell line (Deganuto et al., 2010). However, it
was recently shown that a subpopulation of SH-SY5Y cells appear
to survive to the initial damage of 140 nM UCB by increasing GSH
content, thus becoming more resistant to oxidative stress (Giraudi
et al., 2011).
Finally, even though that microglia and astrocytes are the pre-
dominant sources of pro-inﬂammatory cyto/chemokines,neurons
can also express these factors in disease settings (Ohtori et al., 2004;
Janelsins et al., 2008; Nazmi et al., 2011). Nevertheless, far smaller
concentrations of tumor necrosis factor (TNF)-α than the ones
produced by astrocytes were secreted from UCB-treated neurons
(Falcão et al., 2006; Figure 3D).
Once glial cells degeneration has direct deleterious conse-
quences on the function and survival of neurons, which will
be deprived of their optimal microenvironment, UCB-induced
glial damage cannot be simply considered as marginal events
or secondary reactions to neuronal injury, but rather should be
jointly included in the BIND processes. Therefore, in the follow-
ing sections we will describe how glial cells sense and respond to
UCB as important players in neuronal dysfunction and promising
therapeutic targets.
GLIAL REACTIVITY AND DYSFUNCTION BY BILIRUBIN
The survival and proper function of neurons is ensured by the
large number of glial cells (Streit, 2002). They have acquired a spe-
cial relevance in brain injuries and include OLGs and astrocytes,
as well as microglial cells which share features with immune cells.
Microglia and astrocytes communicate each other through the
cytokine IL-1 and ATP and are recognized as active participants
in various pathological conditions, reason why their activation is
associated with the development and severity of diseases. Once
microglia are activated earlier than astrocytes, it is believed that
they promote the activation of astrocytes (Liu et al., 2011a).
Interestingly, both astrocytes and microglia have lately been
referred to be involved in “synaptic stripping” after axon lesion
(Cullheim and Thams, 2007). Recently, it was observed that
microglia make contacts with neuronal synapses at a rate of about
one per hour with a lasting time of 5min (Wake et al., 2009), being
considered vital members of the “quadripartite synapse,” which
also includes presynaptic and postsynaptic neurons, astrocytes,
and extracellular matrix (Sykova and Nicholson, 2008). There-
fore, we should consider that microglia–neuronal cross-talk is a
key point in guiding microglial activation and that the cytokines
released by activated microglia inﬂuence not only neighboring
neurons but also astrocytes.
Interaction of all these cell types thus fulﬁlls brain function.
In vitro cell models have been used to unravel speciﬁc cell dys-
functionmechanisms byUCB and the intricate signaling processes
comprised, as well to screen target-driven therapeutic agents, in
an attempt to incorporate this heterogeneity to better understand
the basis of BIND pathogenesis. In the following sections, we will
describe the research that is being undertaken using speciﬁc cell
populations.
ASTROCYTES ARE KEY PLAYERS IN BILIRUBIN INJURY
Astrocytes that are the most abundant type of glia (Nair et al.,
2008), outnumbering neurons by over ﬁvefold (Sofroniew and
Vinters, 2010), have multiple homeostatic properties (Orellana
et al., 2009). They are closely associated to neurons, and most
synapses are intimately ensheathed by astrocytes processes. Astro-
cytes, like microglia, may have either a neuroprotective or a neu-
rotoxic role, where the release of pro-inﬂammatory cytokines,
glutamate, ATP, and free radicals may decrease neuronal survival
and increase their susceptibility to neurotoxins. In fact, injuries in
astrocyte function have been recognized as highly contributing to
neuronal dysfunction (Allaman et al., 2011).
First reports on the UCB toxicity to astroglia came out in the
1960s, either in rat cerebellum cultures (Silberberg and Schutta,
1967) or in experimental kernicterus (Chen et al., 1969), in which
the Authors observed swelling of the perivascular astrocyte foot
and evidence of impending cell damage. Access of UCB to neu-
rons was later proposed on the basis of a ﬁrst absorption from
astrocytes foot processes followed by diffusion from presynaptic
astrocytes processes into the dendrites.
In primary cultures of fetal rat glial cells (Amit and Bren-
ner, 1993), as well as in astrocytes (Falcão et al., 2006), toxic
effects of UCB were noticed on cell morphology, cell viability, and
mitochondrial function (Figure 5A). Astrocytes, similarly to neu-
rons exhibited an age-dependent sensitivity to UCB toxic effects.
Decreased expression of Mrp1 and Pgp, observed in immature
astrocytes when compared to more differentiated cells (Watchko
et al., 2001; Falcão et al., 2007a; Sequeira et al., 2007), surely con-
tributes for the increased susceptibility of immature astrocytes to
UCB. Moreover, induction of necrotic-like cell death by UCB was
higher in astrocytes than in neurons, in immature than in mature
cells, and more elevated than its own apoptosis (Figures 3A,B). In
addition,both hypoxia and combined oxygen–glucose deprivation
(OGD) followed by reoxygenation demonstrated to increase astro-
cyte susceptibility to UCB injury (Falcão et al., 2007b), accounting
as risk factors of BIND.
Similarly to neurons, UCB determines a fast increase in the
extracellular glutamate content (Fernandes et al., 2004), mainly in
immature astrocytes (Figure 3C; Falcão et al., 2005) that appears
to result from the inhibition of its uptake by UCB (Silva et al.,
1999), more effective in these glial cells than in neurons (Brito
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FIGURE 5 | Model of astrocytic reactivity to unconjugated bilirubin (UCB)
evidencing the pathways involved in the release of pro-inflammatory
cytokines and in cell demise (A) mediated by mitochondrial (B) and
rough endoplasmic reticulum (ER) (C) abnormalities. UCB causes
inhibition of glutamate uptake and elevation of intracellular calcium (Ca2+)
levels that modulate the exocytosis of glutamate, thus increasing the
extracellular content of glutamate. High concentrations of UCB disrupt
endocytosis in astrocytes and produce mitochondria swelling, mediated by
the opening of the permeability transition megapore, and ER enlargement
probably preceded by ER stress response and release of Ca2+. UCB-induced
apoptosis include mitochondrial permeabilization and cytochrome c efﬂux.
UCB induces the secretion of both tumor necrosis factor (TNF)-α and
interleukin (IL)-1β, which stimulate the synthesis of IL-6 after the ﬁrst 4 h of
interaction. The primary inﬂammatory stimulus causes a rapid and transient
activation of the mitogen-activated protein kinase (MAPK) pathways that
include p38, c-Jun N-terminal kinases (JNK) 1/2, and extracellular signal
regulated kinases (ERK) 1/2, as well as of the nuclear factor-kappaB (NF-κB)
that is translocated to the nucleus. Then, downstream transcription factors
(TF) are activated and the expression of genes involved in cytokine release
and cell death is induced. UCB interacts with the cytoplasmatic membrane of
astrocytes inducing a rapid and sustained upregulation of both TNF-α receptor
(TNFR)1 and IL-1β receptor (IL-1R)1. TNFR1 activation triggers the recruitment
of the receptor-associated factor (TRAF)2, TNF receptor-associated death
domain (TRADD), and receptor-interacting protein (RIP). Formation of an active
IL-1R1 signaling complex mediate the recruitment of IL-1 receptor-associated
kinases (IRAK) and leads to the recruitment ofTRAF6 that is required for NF-κB
mobilization to the nucleus and to the phosphorylation of the three MAPKs.
Activation of this intracellular cascade, upon direct UCB challenge or indirectly
by the increased secretion of TNF-α and IL-1β, lead to a number of astrocytic
death paradigms, which cover a spectrum from apoptosis to necrosis.
et al., 2002), but also from enhanced reactive astrocyte secretion
(Falcão et al., 2006), which may either occur directly from the
cytosol or via regulated exocytosis (Figure 5A). Abnormally pro-
longed exposure to glutamate causes neuronal injury, and such
“excitotoxicity” can be deleterious to neurons and OLGs and cause
disease. Interestingly, this glutamate elicits a fast communication
between astrocytes and adjacent cells in the brain (De Keyser et al.,
2008) and although glutamate-induced Ca2+ inﬂux can trigger
DNA damage by a mitochondrial ROS-mediated mechanism, the
Ca2+was indicated to simultaneously enhance DNA repair capa-
bility, thereby protecting neurons against injury and disease (Yang
et al., 2011).
To the best of our knowledge, our lab provided the ﬁrst evi-
dence that elevated concentrations of UCB trigger the secretion
of TNF-α (Figure 6A) and IL-1β by astrocytes (Figure 6B;
Fernandes et al., 2004) through the increase of TNF-α and IL-1β
mRNA expression and activation of TNF-α-converting enzyme
(TACE) and IL-1β-converting enzyme (ICE), known as caspase-
1, raising the conversion of the cytokine pro-forms into active
forms (Fernandes et al., 2006). Again, immature astrocytes were
the main producers of TNF-α (Figure 3D) and IL-1β (Falcão et al.,
2006).
Effects of UCB at the level of the membrane of astrocytes also
include the inhibition of cell endocytosis (Silva et al., 2001a)
and the upregulation of both TNF-α receptor (TNFR)1 and
IL-1β receptor (IL-1R)1 (Fernandes et al., 2011), triggering the
recruitment of receptors’ molecular adaptors TRAF2 and TRAF6,
respectively (Figure 5). Activation of the three mitogen-activated
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FIGURE 6 |Temporal profile of unconjugated bilirubin-induced (UCB)
activation of inflammatory pathways: a comparison between microglia
and astrocytes. Increased and equivalent release of tumor necrosis factor
(TNF)-α (A) is determined by UCB on both astrocytes and microglia. However,
secretion of interleukin (IL)-1β (B) by astrocytes is much higher in microglia
and earlier produced upon UCB challenge than in astrocytes. Initial effects of
UCB at the level of IL-6 release (C) are of opposite signals. While IL-6
production by astrocytes is depressed in the ﬁrst 4 h of incubation with UCB
before being enhanced, IL-6 secretion by microglia is almost immediately
induced by UCB. These timely differences in the secretion of
pro-inﬂammatory cytokines between astrocytes and microglia should reside
in the former activation of nuclear factor (NF)-κB and mitogen-activated
protein kinases (MAPKs) (D) in microglia than is astrocytes. These features
corroborate the belief that microglia is activated earlier than astrocytes, thus
promoting astrocytic activation. Data, presented as mean±SEM, derived
from Fernandes et al. (2006) and Silva et al. (2010).
protein kinases (MAPK) pathways, p38, JNK1/2, and ERK1/2 is
subsequently achieved, inducing the pro-inﬂammatory cytokine
gene expression and the release of TNF-α and IL-1β. Although IL-
6 expression was initially down-regulated by UCB, it substantially
increased after 6 h of incubation with UCB (Figure 6C; Fernan-
des et al., 2006). Similarly, UCB activated nuclear factor-kappaB
(NF-κB) signaling pathway (Figures 5A and 6D) via activation of
TNF-α/TNFR1 and IL-1β/IL-1R1 cascades (Fernandes et al., 2006,
2007a).
Injury of astrocytes by high levels of UCB determines ER and
mitochondria morphological changes (Figures 5B,C; Silva et al.,
2001a), which have been related with oxidative stress and cell
death in other neurological diseases (Higgins et al., 2010). Even
considering the higher GSH levels and the elevated resistance to
UCB-induced oxidative stress in astrocytes, as compared to neu-
rons, depletion of GSH was still observed after incubation with Bf
concentrations of 0.1 and 1μM (Brito et al., 2008b).
Because all these aspects may contribute to the degeneration
of astrocytes in brain parenchyma, compromising neuronal sur-
vival, and functional recovery after BIND, we propose that astro-
cytes should be considered one of the targets when searching for
novel therapeutics for preventing neurological sequelae by UCB
in conditions where the most used clinical approaches evidence
to fail.
MICROGLIA IN THE PROCESS OF BILIRUBIN-INDUCED
INFLAMMATION
Microglia reside within the CNS parenchyma, in both gray and
white matter (WM), and constitute about 12% of total glial cell
population (Aloisi, 2001; Ladeby et al., 2005). In the surveil-
lant/vigilating state, previously designed as resting state,microglia
through their ﬁne processes have an elevated motility, higher
than that of astrocytes, allowing them to constantly monitor their
microenvironment (Davalos et al., 2005;Nimmerjahn et al., 2005).
Therefore, microglia were shown to be involved in neurogenesis,
postlesional tissue repair, and“synaptic stripping”(Graeber,2010).
Microglia should be considered an additional target to protect
in hyperbilirubinemia because they play a major role in synap-
tic pruning during postnatal development, as suggested by data
obtained in mice during normal brain development (Paolicelli
et al., 2011). Moreover, phagocytosis of tissue debris by microglia
is essential for tissue homeostasis and is considered to be associated
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to a neuroprotective outcome. The ﬁrst reaction of microglia
toward UCB insult is the increase in phagocytosis (Figure 7),
probably as an attempt to constrain the lesion extent, although
only transiently exerted once increased levels of apoptosis were
shown to follow until the 12 h of incubation (Silva et al., 2010).
However, microglia can also be activated or overactivated,
depending on the stimuli, thus becoming neurotoxic (Carson
et al., 2007). When activated by UCB microglia change from
an elongated morphology to an amoeboid-appearance (Gordo
et al., 2006) and even can dye by several pathways (Silva et al.,
2010). Maximal levels for caspase-8 (extrinsic pathway), caspase-9
(intrinsic) and the effector caspase-3 were obtained at 6 h of treat-
ment.Moreover, the cells release pro-inﬂammatory cytokines such
as TNF-α (Figure 6A), IL-1β (Figure 6B), and IL-6 (Figure 6C),
which parallels the alterations in cell morphology. Similarly to
astrocytes,UCB activatesMAPKs andNF-κB inmicroglia.MAPKs
involvement andNF-κBengagement inUCB-challengedmicroglia
occurs at an early time point (Figure 6D), and appear to underlie
the phagocytic activity observed at 4 h incubation and the inﬂam-
matory phenotypes initiated at 2 hwith peak levels at 4 and 24 h for
TNF-α, at 8 h for IL-6, and at 12 h IL-1β (Figure 6D). TNF-α has
shown to have a critical role in several neuropathologic disorders.
Indeed, TNF-α lies at the beginning of a signal cascade that may
lead to neuronal cell death, potentiates glutamate neurotoxicity,
and can stimulate the production of IL-1β, IL-6, and other cyto-
toxic cytokines (Lee et al., 1993; Chao and Hu, 1994). Moderate
upregulation of cyclooxygenase (COX)-2 and of matrix metallo-
proteinase (MMP)-2 and -9 activities were induced by UCB only
after 12 and 24 h incubation. The most marked effect of UCB on
microglia was shown to consist in the elevated levels of IL-1β what
was curiously relatedwith increasedTau phosphorylation (Li et al.,
2003) and loss of neuronal integrity (Depino et al., 2005).
Microglia, similarly to neurons and astrocytes (Falcão et al.,
2006), also release the cytotoxic molecule glutamate (Piani et al.,
1991) when exposed to UCB (Gordo et al., 2006). The levels were
found to be threefold enhanced when compared to those in astro-
cytes and sixfold to those in neurons (Brites et al., 2009). Release
of glutamate by microglia was observed by other neurotoxins, is
related to disorders of synaptic plasticity (Patrizio and Levi, 1994;
Maezawa and Jin, 2010) and indicated to participate in microglial
neurotoxicity (Barger and Basile, 2001; Liang et al., 2008).
What triggers increased microglial activation is still unclear but
oxidative stress, resulting from increased ROS, appears to have a
determinant role (Floyd and Hensley, 2002; Lu et al., 2004). As it
can be seen in Figure 7, UCB is implicated in ROS generation by
neurons. After CNS injury, microglia can rapidly populate the site
of injury (Morgese et al., 1983) and migration of these cells is trig-
geredby compounds releasedby thedamaged tissue (Kurpius et al.,
2007), such as ATP and NO (Duan et al., 2009). Actually, ATP was
shown to be released from neurons treated with UCB (Vaz et al.,
2010), and NO generated by OLGs (Genc et al., 2003), neurons
(Vaz et al., 2011b), and microglia (Silva et al., 2012) upon exposure
to UCB (Figure 7). Therefore, since microglial cells themselves
can release ATP, it is possible that a positive feedback mechanism
perpetuates migration and a gradient of NO will direct migra-
tion to the site of injury, as the stopping location for microglial
cells reparative functions (Samuels et al., 2010). These include
phagocytosis of cellular debris leading to the axonal sprouting and
reestablishment of synaptic contacts (Morgese et al., 1983; Ngu
et al., 2007). Nevertheless,microglial phagocytosis of stressed neu-
rons also contributes to their loss. Moreover, excessive microglial
production of NO induced by UCB in hippocampal slices (Silva
et al., 2012)may lead to increased cell death. In fact, and in contrast
to the“protective”effects exerted by microglia in preventing exces-
sive glutamate,microglia additionally contribute to the generation
of NO, an important mediator in microglia-induced neuron death
(Golde et al., 2002; Graber et al., 2012). Generation of NO may
derive from iNOS activation,which once activated produces mod-
erate levels of NO chronically without any requirement for further
activation (Brown, 2010), or from constitutive NOS, probably
originating in the case of UCB an overproduction that may inhibit
phagocytosis (Kopec and Carroll, 2000), as we observed following
the 4 h of incubation (Silva et al., 2010).
Furthermore, microglia exhibit partial or complete fragmenta-
tion of cytoplasm, as well as nuclear condensation, when exposed
to UCB for longer periods of time (Silva et al., 2010), thus com-
promising any beneﬁcial effect that they could have in BIND
protection. This feature is designed as dystrophy of microglia
(Streit et al., 2008),or cytorrhexis (Fendrick et al., 2007;Hasegawa-
Ishii et al., 2011) and is an indication of microglia degeneration
and senescence (Streit et al., 2004).
Collectively, we may assume that the release of cytokines and,
eventually other soluble products from microglia activated by
damaged neurons, contributes to the initiation and maintenance
of astrogliosis observed in kernicterus (Steinborn et al., 1999),
and an underlying component of a diverse range of diseases and
associated neuropathologies. Thus, development of targeted anti-
microglial activation therapies might help to attenuate reactive
astrogliosis and generate a more beneﬁcial environment to protect
brain from UCB-induced neurotoxicity.
BILIRUBIN DAMAGES MYELINATING GLIA
In the CNS, WM is primarily comprised of axonal bundles
ensheathedwithmyelin,which reduces axonal loss. The cells form-
ing these sheaths are theOLGs that spirallywrap segments of axons
during late fetal and early postnatal stages. Just before and after
birth, oligodendrocyte precursor cells (OPCs) multiply rapidly,
differentiate into myelinating OLGs, and develop processes, which
are then involved in the formation of myelin (Arai and Lo, 2009;
Piaton et al., 2010). Reciprocal communication between neurons
and OLGs are essential for myelin biogenesis and myelin repair
(Piaton et al., 2010). When OPCs and OLGs are damaged there
is a loss of myelin synthesis and interruption of proper axonal
function and, consequently, of neuronal connectivity and func-
tion (Arai et al., 2009). However, compared to the mechanisms
of neuronal injury in gray matter, WM pathophysiology remains
relatively understudied and poorly understood, probably account-
ing for the scarce information about its inﬂuence on BIND and
kernicterus.
Moderate perinatal systemic inﬂammation and hypoxia–
ischemia, and perhaps most important, combinations of these,
are related to deﬁcient OPCs maturation, with reduced density
of myelinating OLGs and disruption of the expression of several
transcription factors important in OPCs maturation, thus causing
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FIGURE 7 | Overview of the effectors that may be involved in microglia
dialog with other glial cells and neurons, upon exposure to
unconjugated bilirubin (UCB). Extracellular increased levels of glutamate by
UCB-induced secretion from astrocytes, microglia, and neurons, as well as by
astrocytic uptake inhibition, together with the release of inﬂammatory
mediators, such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and IL-1β
from astrocytes and microglia (A), are included in cross-talk effectors. Also
comprised are members of the oxidative stress, including the reactive oxygen
species (ROS) produced by neurons and oligodendrocytes (OLGs), as well as
nitrosative stress by nitric oxide (NO) generated by microglia, neurons, and
OLGs, and elevated release of ATP from neurons, during exposure to UCB.
(B) Phagocytosis upon short stimulation with UCB is visualized in microglia
immunostained with an antibody against Iba1 (red) and using Hoechst 33258
stain to visualize the nucleus (blue), by counting the number of ingested
ﬂuorescent latex beads (green). Microglia intervenes in glutamate tissue
(Continued)
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FIGURE 7 | Continued
homeostasis by both releasing and retaining glutamate when exposed to
UCB. But microglia also reacts to UCB stimulus, very rapidly, through the
activation of mitogen-activated protein kinases (MAPKs), mainly the c-Jun
N-terminal kinases (JNK)1/2 and p38, and of the nuclear factor-kappaB (NF-κB)
that is translocated to the nucleus, determining the activation of transcription
factors (TF) and further release of cytokines. These pathways may mediate
both the phagocytic and the inﬂammatory phenotypes and are related with a
shift from an elongated morphology to a large and amoeboid shape (1).
Longer exposure to UCB leas to fragmented and condensed cytoplasm, a
feature of dystrophic microglia (2) indicative of cell degeneration and
senescence. The multifaceted proﬁle of microglia is determined by the
stimulus type and duration, and dialog between cells. Although microglia
activation may promote astrocytic reactivity, the release of pro-inﬂammatory
cytokines, glutamate, and NO from these cells may exacerbate microglia
reactivity, which by propagating inﬂammation will sensitize neurons and
decrease their survival upon UCB exposure. Moreover, astrocytic
deregulation and degeneration by UCB determine inaccurate
neuron–astrocyte interactions, causing neuritic arborization and synaptic
transmission impairment, favoring brain damage. OLGs do not play a role in
promoting inﬂammation although, like neurons, are damaged by UCB and
associated inﬂammatory processes.(C) OLGs and dorsal root ganglion
neurons co-cultures incubated for 24 h with 100μM human serum albumin
(HSA) at 7 days in vitro evidence an increased number of myelinating OLGs.
(D) Incubation with 50μM UCB plus 100μM HSA reveal a delayed
myelination once a number of neuroﬁlaments are still not myelinated when
compared to the image in (C). To evaluate myelination, OLGs were ﬁxed at
21 days in vitro and immunolabeled for myelin basic protein (MBP, red) and
neuroﬁlament (NF, green). Nuclei were counterstained with Hoechst 33258
dye (blue).
long-lasting effects (Favrais et al., 2011; Volpe et al., 2011). In
these circumstances, susceptible microglia during early postna-
tal development may modify their functional capacity, similarly
to a “primed” state, and become more susceptible to a secondary
reaction by injury or to the effects of aging (Harry andKraft, 2012).
Several years ago, it was reported that UCB adversely affects
myelination in tissue cultures of rat cerebellum (Silberberg and
Schutta, 1967). Binding of UCB to myelin basic protein (MBP)
was later on evidenced (Gurba and Zand, 1974) and suggested to
provide a mechanism for retention of UCB in the brain, while
causing the inhibition of cerebellar protein synthesis by an unde-
ﬁned mechanism. Curiously elevated concentrations of UCB were
found in the CNS myelin fraction after injection of UCB into
rats (Hansen et al., 2001). Recently, by using cranial ultrasound
and MRI scans, Gkoltsiou et al. (2008) observed abnormal WM
signal intensity in 10/11 later scans in infants that have shown
to be in risk of kernicterus, as well as delayed myelination in
some of them. These authors suggested that reaction to UCB
neurotoxicity in extremely immature brains may be delayed as
compared to term or near term infants, determining the observa-
tion of changes only in late scans. Impairments in myelination and
WM involvement in UCB encephalopathy were also observed at
autopsy (Ahdab-Barmada andMoossy,1984;Koo andRoessmann,
1988). Furthermore, separation of the myelin lamellae was visu-
alized in a model of experimental kernicterus (Chen et al., 1971),
and myelin ﬁgures surrounding vacuoles, bits of cytoplasm, and
other intracytoplasmic debris were identiﬁed in the Gunn rat (Jew
and Williams, 1977). In addition, a decreased density of myeli-
nated ﬁbers was recently evidenced in the cerebellum of a preterm
infant who died from kernicterus (Brito et al., 2012).
In vitro studies have indicated that UCB is responsible for
decreased OPCs (Barateiro et al., 2010) and OLGs viability (Genc
et al., 2003). OPC displayed increased apoptosis (Barateiro et al.,
2010), and necrosis-like cell death upon UCB exposure, mediated
by early signals of ER stress followed by mitochondrial dysfunc-
tion (Figures 8A,B). Indeed, UCB activates the unfolded protein
response in OPCs by up-regulating the expression of GRP78 and
GRP94. This is not without precedent once recent reports have
shown that both UCB and Bf up-regulate many genes involved in
ER stress both in SH-SY5Y (Calligaris et al., 2009) and Hepa 1c1c7
cells (Oakes and Bend, 2010). Other effects produced by UCB
on OPCs include intracellular Ca2+ overload, ROS generation
and JNK activation (Barateiro et al., 2010), while NO production
FIGURE 8 | Exposure of oligodendrocyte precursor cells (OPCs) to
unconjugated bilirubin (UCB) leads to mitochondrial dysfunction,
followed by calpain activation, and cell death. Primary cultures of OPCs
were isolated from mixed glial cultures and stimulated to differentiate.
OPCs were treated with 100μM of human serum albumin (HSA; control) or
50μM UCB plus 100μM HSA for 24 h (UCB). Mitochondrial functionality
was evaluated by Mitotracker Red. Endoplasmic reticulum stress was
assessed by the activity of calcium-dependent calpain using a speciﬁc
calpain substrate. Necrotic-like cell death was evaluated by propidium
iodide (PI) through the emission of red ﬂuorescence. (A) Representative
results of one experiment. (B) Graph bars represent the fold increase in
staining intensity comparatively to control (mean±SEM) in labeled active
mitochondria (red), in calpain activity (blue), and in PI+ cells (red) from at
least three independent experiments performed in duplicate. (C) Effects
produced by UCB in OPCs start by mitochondrial dysfunction that induces
the increase in intracellular calcium levels and activation of calpains. This
cascade of events culminates in OPCs demise. Impairment of OPCs
differentiation into oligodendrocytes by UCB will determine defective
myelination. Scale bar represents 20μm. **p <0.01 vs. control. Data
derived from Barateiro et al. (2010).
via UCB-induced iNOS mRNA expression was observed in OLGs
(Genc et al., 2003). Interestingly, no release of TNF-α, IL-1β, or
glutamate could be noticed in OPCs cultured with UCB (Barateiro
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et al., 2010). A consequence of the sustained high concentration
of intracellular Ca2+ is the activation of calpains by UCB, com-
promising cellular speciﬁc functions, and promoting cell death
(Figure 8C). Moreover, UCB also delays differentiation of OPCs
enhancing the number of immature (NG2+) cells and reducing
that of OLGs (MBP+) when compared to vehicle-treated OPCs.
These ﬁndings indicate that UCB, besides compromising OPCs
proliferation, may also delay myelination (Figures 7C,D). There-
fore, hyperbilirubinemia during the early phase of developmental
myelination, where an unusual synthesis rate of myelin structural
proteins are necessary (Nave, 2010),may impair OPCs differentia-
tion into OLGs triggering defective myelination and neurological
damage.
Collectively, these ﬁndings indicate that UCB compromises
myelinogenesis and determines degeneration and eventual loss of
functional myelin sheaths, features that should be taken in consid-
eration for BIND neuroprotective strategies, mainly in premature
babies. Indeed, neuroprotection cannot be truly attained with-
out effective oligoprotection (Arai and Lo, 2009). Thus, OPCs
count among the most vulnerable cells of the CNS due to their
complex differentiation program (Bradl and Lassmann, 2010),
and neuroinﬂammation, and OLGs dysfunction were shown as
a main cause of axonal loss (Edgar et al., 2010). Dysregula-
tion of myelination pathways by UCB surely deserves further
investigation.
ROLE OF NEUROINFLAMMATION IN BIND
Some past studies have evidenced that UCB inhibits the function
of the polymorphonuclear leukocytes and lymphocytes (Table 1;
Thong and Rencis, 1977; Thong et al., 1979; Iwanaga et al., 1987;
Haga et al., 1996a,b). Inﬂammatory properties by UCB have
lately been observed in a mice model of intracerebral hemor-
rhage (Loftspring et al., 2011) and immunotoxic effects on both
bone marrow and spleen cell suspensions obtained from mice
(Khan and Poduval, 2011). As previously commented for neural
cells, UCB has shown to trigger intrinsic and extrinsic pathways
activation, GSH depletion, p38MAPK activation, and oxidative
stress in splenocytes. Production of systemic pro-inﬂammatory
mediators ultimately activates microglia, as well as it causes neu-
ronal apoptosis and disruption of BBB and neuroinﬂammation
(Morandi et al., 2011; Daulatzai, 2012). This alteration disrupts
the delicate balance between neuro-glial interactive components
resulting in deﬁcient neuritic arborization and synaptic transmis-
sion (Rossi and Volterra, 2009), as well as in impaired mem-
ory, neural plasticity, and neurogenesis (Yirmiya and Goshen,
2011).
As commented before, UCB is able to cause the reactivity of
rat cortical astrocytes and microglia (Table 1), which in turn exac-
erbate inﬂammation (Sofroniew and Vinters, 2010) and increase
BBBpermeability by acting on endothelial cells and tight junctions
(Nair et al., 2008). While the secreted levels of TNF-α (Figure 6A)
are at the same order either in astrocytes or in microglia exposed
to UCB, those of IL-1β and IL-6 are increasingly produced by
microglia (Figures 6B,C) and earlier secreted (Figure 6D), sug-
gesting that microglia participate in astrocyte reactivity by UCB
and corroborating microglia faster response to stimuli (Liu et al.,
2011a). Release of pro-inﬂammatory cytokines, as well as of ROS
and NOS, can disrupt nerve terminals activity causing dysfunction
and loss of synapses by UCB (Haustein et al., 2010). Therefore,
UCB-induced inﬂammatory processes have emerged as a critical
concept to understand the neurotoxic effects of UCB.
Unconjugated bilirubin-induced immunostimulation involves
the activation of NF-κB signal transduction pathway in both astro-
cytes (Fernandes et al., 2006, 2007a, 2011) and microglia (Silva
et al., 2010), one of the most important determinants of inﬂam-
matory gene expression and cytokine synthesis in glia (Table 1;
Figure 7). Activation of NF-κB was mainly evidenced in imma-
ture astrocytes and increase by risk factors common in neonatal
life (Falcão et al., 2007b), pointing to an added determinant for
the susceptibility of preterm infants. Interestingly, activation of
this transcription factor evidenced to precede MAPK activation
and to be directly associated with TNF-α and IL-1β secretion,
as well as with the loss of cell membrane integrity, but not the
release of glutamate by astrocytes (Fernandes et al., 2006, 2007a;
Brites et al., 2009). As already noticed for MAPKs activation and
cytokine release, activation of NF-κB was faster in microglia than
in astrocytes, as well (Figure 6D). It should be emphasized that
activation of NF-κB, although not as markedly as in astrocytes
and microglia, was also induced in neurons cultured with UCB
(Figure 2),mainly in the immature ones (Falcão et al., 2006).How-
ever, only mild levels of IL-6, even less of TNF-α, and undetectable
of IL-1β secretion were obtained under UCB exposure. Actually,
NF-κB has diverse functions in the CNS, depending on the cellu-
lar context. Activation of NF-κB in neurons is implicated in axon
growth, which is important for long-term memory (Kaltschmidt
and Kaltschmidt, 2009; Teng and Tang, 2010). In this context, NF-
κB in the synapse can be activated and transported retrogradely
to the cell nucleus to regulate neural development, plasticity, and
even neurogenesis (Gutierrez and Davies, 2011; Yakovleva et al.,
2011). Thus, it is recognized as a major regulator of the growth
and morphology of process initiation to stages when neurons are
establishing functional connections and dendritic spines (Gutier-
rez and Davies, 2011). Collectively, these ﬁndings indicate that
while NF-κB inhibition in glia might ameliorate disease, induced
activation in neurons might enhance memory.
Associated conditions, such as sepsis,during,or followingmod-
erate to severe hyperbilirubinemia, are believed to contribute to
BIND(Connolly andVolpe,1990;Kaplan andHammerman,2005)
and bacterial infection is considered a risk factor in the devel-
opment of kernicterus (Pearlman et al., 1980; Yeung and Ngai,
2001; Figure 9). Moreover, in a Nigerian study, sepsis was the
sole cause of hyperbilirubinaemia in 5% of the cases with severe
neonatal jaundice (Dawodu et al., 1984). In in-vitro experimen-
tal conditions, addition of lipopolyssacharide (LPS) to cultures of
astrocytes or neurons was shown to increase UCB-induced cell
death (Figures 3A,B), as well as the release of TNF-α (Figure 3D)
and IL-1β by astrocytes (Fernandes et al., 2004).
Addition of LPS to astrocytes has revealed to increase UCB-
induced necrosis mainly in mature cells (Figure 3A), apoptosis
in old ones (Figure 3B; Falcão et al., 2005), and the release of
IL-1β (Fernandes et al., 2004) and TNF-α at all cell ages (Falcão
et al., 2005). Interestingly, increased secretion of TNF-α by LPS
was also evidenced in immature neurons when co-incubated with
UCB (Figure 3D). Although LPS has previously shown to inhibit
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Table 1 | Immunostimulant and immunotoxic effects of unconjugated bilirubin (UCB) in cell primary cultures, cell suspensions, and animal
models.
Model Cell Effect Reference
UCB Polymorphonuclear leukocytes ↓ Bactericidal activity (Thong and Rencis, 1977)
UCB Polymorphonuclear leukocytes ↓ Microbicidal function (Thong and Rencis, 1977)
UCB Polymorphonuclear leukocytes ↓ Fungicidal capacity (Thong et al., 1979)
UCB Cytotoxic T lymphocytes ↓ Activity (Haga et al., 1996a)
UCB Lymphocytes ↓ MHC-unrestricted
cytotoxicity
(Haga et al., 1996b)
UCB Astrocytes ↑ Release of IL-1β, TNF-α, and
IL-6
(Fernandes et al., 2004)
UCB Astrocytes ↑ Activation of NF-κB and
MAPK signaling cascades
(Fernandes et al., 2006, 2007a)
UCB Microglia ↑ Release of IL-1β, TNF-α, and
IL-6
(Gordo et al., 2006)
UCB Microglia ↑ Activation of NF-κB (Silva et al., 2010)
↑ Activation of MAPK
Activation
↑ Metalloproteinases 2 and 9
↑ COX-2
UCB+LPS vs. UCB Astrocytes ↑ Necrosis (Fernandes et al., 2004; Falcão et al., 2005)
↑TNF-α and IL-1β
UCB+LPS vs. UCB Neurons ↑ Apoptosis (Falcão et al., 2007c)
↓ Neurite extension
UCB+TNF-α vs. UCB Neurons ↑ Apoptosis (Falcão et al., 2007c)
UCB+TNF-α+ IL-1β vs. UCB Neurons ↑ nNOS (Vaz et al., 2011b)
↑ NO
↑ Apoptosis (caspases 3, 8, 9
and tBid)
↑ P-JNK1/2
↓ Viability
UCB Bone marrow cell suspension ↑ Apoptosis (Khan and Poduval, 2011)
↑ Necrosis
UCB Spleen cell suspension ↑ Apoptosis (Khan and Poduval, 2011)
↑ Necrosis
UCB injection ↓ Viability of bone marrow
cells
(Khan and Poduval, 2011)
↓ Viability of splenocytes
↓ Splenocyte proliferative
response
↑ p38MAPK activation
↑ ROS
↓ GSH
Mice model of intracerebral
hemorrhage
↑ Edema (Loftspring et al., 2011)
↑ ICAM-1 expression
↑ Neutrophil inﬁltration
↓ Perihematomal microglia
immunoreactivity
MHC, major histocompatibility complex; IL-1β, interleukin-1β;TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; NF-κB, nuclear factor-kappaB; MAPK, mitogen-activated
protein kinase; COX-2, cyclooxygenase-2; LPS, lipopolysaccharide; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; tBid, truncated BH3-interacting domain
death agonist; P-JNK1/2, phospho-c-jun NH2-terminal kinase1/2; ROS, reactive oxygen species; GSH, reduced glutathione; ICAM-1, intercellular adhesion molecule-1.
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FIGURE 9 | Overview of the main alterations occurring at the
blood–brain barrier (BBB) and in the interplay between neurons and
glial cells during severe hyperbilirubinemia (A) and associated infection
(B).The BBB is composed by endothelial cells (orange) and their tight (TJ)
and adherens junctions (AJ), astrocyte end-feet (light blue spots),
perivascular microglia (greenish-brown), pericytes (light-green), and the
basement membrane (yellow). Circulation of unconjugated bilirubin (UCB) in
the blood (yellow bullets) is provided by its binding to human serum
albumin, but when the UCB levels greatly increase, interaction of unbound
(free) fraction of UCB (Bf) with the BBB is enhanced, as well as its passage
into the brain (A), by passive or facilitated diffusion. Entrance will be also
facilitated by the increased number of caveolae and caveolin-1 upregulation.
Then, mainly after long-term exposure, UCB decreases zonula occludens-1
and β-catenin levels, and thusTJ strands and cell-to-cell contacts, favoring
UCB passage across the BBB. Pericytes will be damaged and glutathione
homeostasis disruption, together with increased nitric oxide synthase
expression, nitrite production, and cytokine release will cause endothelial
cell degeneration. In the brain parenchyma, elevated levels of UCB will
surpass protective mechanisms (see Figure 1) and will cause neuron (pink)
degeneration and release of pro-oxidant factors (orange bullets), microglia
activation that will ﬁrst phagocyte debris (pink bullets), and together with
astrocytes (blue) reactivity will secrete pro-inﬂammatory mediators
(greenish-brown bullets). In addition, decreased number of myelinating
oligodendrocytes (solid-green) is also observed. (B)When sepsis is
associated to hyperbilirubinemia, increased alterations at structural and
functional levels are produced. Endothelial cell and astrocyte end-feet
degeneration, modiﬁed basement membrane composition, tight junction,
and transporter system impairment, vascular protein leakage, extensive
extracellular edema, and activation of metalloproteinases are hallmarks of
BBB impairment. Facilitated entrance of blood-borne harmful substances
may accelerate neuron degeneration and activate microglia and reactive
astrocytes leading to the release of cytokines further damaging neurons and
detrimentally affecting vascular endothelium. Cross-talk between
monocytes and endothelial cells in this inﬂammatory state leads to
reciprocal activation of the two cell types, allowing the diapedesis of
monocytes and lymphocytes. Leukocytes extravasation across the activated
endothelium includes its arrest and adhesion, as well as alterations in their
morphology and transmigration. Alterations in BBB dynamic properties may
favor the presence of albumin carrying UCB (1) and increased passage of
lymphocytes (2) into the brain parenchyma. In this condition, astrocytes
become over-reactive, microglia will acquire inﬂammatory/senescent
phenotypes and both neurons and oligodendrocytes will degenerate. Thus,
therapeutic strategies directed at controlling the activation of microglia and
astrocytes, and the excessive production of pro-inﬂammatory mediators and
pro-oxidant factors may add on the prevention and recovery of neurologic
sequelae resulting from unconjugated hyperbilirubinemia.
glutamate uptake (Parry et al., 2010), elevation of extracellular
glutamate when neurons, astrocytes, and microglia were simulta-
neously treated with LPS and UCB was not sensed (Figure 3C;
Fernandes et al., 2004; Falcão et al., 2005). The same was observed
in astrocytes when co-incubatedwithUCB andTNF-α (Fernandes
et al., 2004). However, when neurons were treated with UCB plus
TNF-α+ IL-1β, these cytokines were shown to have cumulative
effects on the generation of NO and activation of nNOS, JNK1/2,
and caspase cascades (Vaz et al., 2011b). Increased cleavage of Bid
into truncated Bid (tBid), as well as cytotoxic potential, was also
observed (Figure 2; Table 1). These events provide a reason for the
risk of sepsis in BIND and point it as a potential target for thera-
peutic intervention in the BIND prevention. Also remarkable was
the observation that neurons previously exposed to UCB evidence
an increased susceptibility to a subsequent inﬂammatory insult
with LPS or TNF-α (Falcão et al., 2007c), suggesting that priming
of neurons by UCB may result in long-lasting neurological dys-
function, as observed for early-life seizures through enhanced and
persistent glial activation in adult life (Somera-Molina et al., 2007).
Inﬂammatory priming was also shown to inﬂuence dopaminergic
neurons sensitivity to subsequent environmental toxins and sug-
gested to contribute to neurodegenerative diseases (Mangano and
Hayley, 2009). Moreover, microglial priming by acute or chronic
stresswas shown to predispose the brain to neurodegeneration and
to affect disease progression as well (Frank et al., 2012; Ramaglia
et al., 2012). Microglia activation was observed in the Gunn rats
at 8 weeks of age and suggested to contribute to chronic neuronal
inﬂammation (Liaury et al., 2012) and behavioral abnormalities
similar to schizophrenia (Hayashida et al., 2009). These ﬁndings
may have a high relevance in the evaluation of potential lasting
sequelae by unconjugated hyperbilirubinemia and surely deserve
further investigation.
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Prostaglandin E (PGE), also considered one mediator in neu-
roinﬂammatory processes, originates from the degradation of
arachidonic acid through the sequential actions of COX-1 and
COX-2, and three terminal PGE synthases (PGES) one cytoso-
lic and two membrane associated PGES, the mPGES-1 and the
mPGES-2. COX-1 is expressed constitutively at very low levels in
the brain,while COX-2, the inducible isoform, is acutely expressed
in several cell types after brain injury (Zhuang et al., 2003). COX-
2 is induced by pro-inﬂammatory challenges (Font-Nieves et al.,
2012) and pointed as a defensive response to the excess of gluta-
mate, at least in neurons (Bidmon et al., 2000). LPS was shown
to signiﬁcantly induce PGES-1 in microglia (de Oliveira et al.,
2008), as well as PGE2 release from astrocytes by the stimulation of
both the constitutive and inducible COX isoforms (Pistritto et al.,
1998, 1999). Intriguingly, studies in COX-deﬁcient cells and using
COX inhibitors evidenced that COX-2 mediated the production
of PGE2, and COX-1 deﬁciency further increased PGE2 produc-
tion after LPS treatment (Font-Nieves et al., 2012). In fact, the
contribution of these enzymes varies accordingly with the stim-
uli and cell type. While UCB/HSA= 0.5 revealed to moderately
increase COX-2 in microglia (Silva et al., 2010) no effects on basal
PGE2 release were produced by 10μM Bf on primary cultures of
rat hypothalamic astrocytes (Mancuso et al., 1997). Nevertheless,
in rat cortical astrocytes the same Bf amount was able to increase
PGE2 production (Vairano et al., 2001). Since no other studies
on PGE2 increased production by UCB in the presence or in the
absence of HSA can be found in the literature, further studies
should attest on the effects of UCB on the PGE2 production, on
whether it should be taken or not as an index of inﬂammation, and
on its invariable coupling to COX-2 activation, since LPS-induced
mPGES-1 synthesis showed to not strictly be coupled to the syn-
thesis of COX-2 in activated primary rat microglia (de Oliveira
et al., 2008).
Neuronal and glial interplay may reinforce the cascade of
inﬂammatory signaling in astrocytes and microglia interfering
with the reactivity of each other and enhancing detrimental out-
comes in neurons (Figure 7). Conditioned media obtained from
either UCB-treated neurons (NCM) or UCB-treated astrocytes
(ACM) revealed to be able to modulate microglia response, lead-
ing to an enhanced secretion of IL-6 while decreasing that IL-1β
(Silva et al., 2011). NCM also showed to down-regulate TNF-
α production by microglia, and to increase NO production and
MMPs activities, thus accounting to microglia demise. In con-
trast, ACM protected microglia from loss of viability by UCB, in
line with the property of reactive astrocytes in facilitating activa-
tion of distant microglia,while inhibiting microglial activities (Liu
et al., 2011a) and preventing overactivation (Renault-Mihara et al.,
2008). These results emphasize the ability of neurons and astro-
cytes to modulate the pro-inﬂammatory properties of microglia.
However, evaluation of neuroprotective or neurotoxic responsive-
ness of cells to a certain stimulus is only possible if unrestricted
dialog between neurons and glial cells is achieved, as the one
allowed by organotypic-cultured slices.
Brain slice models offer unique advantages over other in vitro
platforms in that interactions between neurons or between neu-
rons and glial cells are fundamentally preserved replicating many
aspects of the in vivo context (Cho et al., 2007; Lossi et al., 2009). In
hippocampal slices incubated with UCB microglia showed to con-
tribute to the release of NO, thus potentiating nitrosative stress.
However, and alike astrocytes (Matute et al., 2007),microglia seem
to participate in the homeostasis of glutamate by promoting its
uptake (Silva et al., 2012), as a way of contributing to restoration
of homeostasis (Shaked et al., 2005). In fact, microglia express the
glutamate transporter 1 (Nakajima et al., 2001), thus reinforcing
the neuroprotective role of microglia (see Role of Neuroinﬂamma-
tion in BIND). By using organotypic-cultured hippocampal slices,
depleted, or not-depleted in microglia (Silva et al., 2012), the high-
est extracellular levels of glutamate were obtained in microglia-
depleted slices, thus corroborating the participation of microglia
in the homeostasis of glutamate, protecting neurons against exci-
totoxicity. Indeed, it was recently considered that depending on
the stimuli,microglia can adopt a phenotype that facilitates rather
than impairs glutamate clearance, as a way of contributing to
restoration of homeostasis (Shaked et al., 2005). Nevertheless,
other studies underscore glutamate’s key role in microglial neu-
rotoxicity (Barger and Basile, 2001; Liang et al., 2008) that may
be related to a more “silent” microglia resulting from detrimen-
tal effects over the course of the injury upon various regulatory
processes (Sargsyan et al., 2011; Harry and Kraft, 2012).
Once degeneration of glial cells has direct deleterious effects on
neuronal function and survival, it will be then important to look
forUCB-inducedpathophysiological alterations as integratedphe-
nomena (Figure 7), only achieved with organotypic slice cultures.
These cultures will be ideal for looking at the mechanisms of neu-
roinﬂammation and the death of neurons. Their potential for drug
discovery is substantial once microglial and astrocytic activation
could be speciﬁcally targeted to preserve cross-talk between neu-
rons and glia, constituting new strategic therapeutics to prevent
BIND.
BIND: IN SEARCH OF POTENTIAL NEUROTHERAPEUTICS
Incidence of kernicterus varies from 1:30 000 to 1:100 000 births
(Manning et al., 2007), but can be higher in developing coun-
tries. Excessive hyperbilirubinemia in human neonates may cause
permanent dysfunction of the auditory system, as assessed with
BAEPs (Rice et al., 2011). Phototherapy has been a widely and
successfully used therapy to reduce the levels of UCB by trans-
forming UCB in the skin into water-soluble isomers that are
cleared without the need of liver conjugation (Stokowski, 2011).
Guidelines for the management of hyperbilirubinemia in new-
born infants and recommendations to use phototherapy were
published by the American Academy of Pediatrics (2004) and
Bhutani (2011), respectively. If phototherapy fails in reducingUCB
levels, or at the readmission of very ill infants, aggressive man-
agement, as exchange transfusion (ET), is usually recommended.
Administration of albumin 1 h prior to ET was shown to signif-
icantly reduce the tissue-bound UCB and to increase ET efﬁcacy
(Shahian and Moslehi, 2010; Mitra et al., 2011). However, ET is
not always successful in preventing acute bilirubin encephalopathy
and adverse outcome (Mukhopadhyay et al., 2010), and compli-
cations such as thrombocytopenia and seizure were indicated to
be present in 21.5% of jaundiced neonates performing such inter-
vention (Davutoglu et al., 2010). Since kernicterus continues to
occurwhereas it ought to be avoidable (Hansen,2011), recognition
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of new therapeutic modulation capacities as adjunctive therapies
may contribute to a more consistent regimen for treatment and
prevention of kernicterus.
Furthermore, once the threshold for UCB neurotoxicity is
unknown, and kernicterus was only evidenced in 5% of yellow
brains ensuing from jaundiced infants at autopsy, as described by
Schmorl and cited by Hansen (2000b), these other cases proba-
bly resultant from moderate levels of UCB may also have harmful
consequences.We speculate that neonatal hyperbilirubinemia, like
perinatal infection/inﬂammation (Favrais et al., 2011), may dis-
rupt the neurodevelopmental program and lead to potential life-
time effects, mainly in preterm infants, warranting an intensiﬁed
search for neuroprotective actions.
Minocycline can be an effective treatment in neurological dis-
eases associated with both oxidative stress (Zhong and Lee, 2007)
and inﬂammation (Chu et al., 2007), by inhibiting microglia
activation (Tikka et al., 2001; Suzuki et al., 2010), caspase-1
expression (Kim and Suh, 2009), and both caspase-dependent
and -independent programmed cell death (Ossola et al., 2012;
Figure 10). It also induces autophagic cell death (Liu et al., 2011b)
and decreases glutamate excitotoxicity (Maier et al., 2007), NO
production (Levkovitz et al., 2007), activation of NF-κB (Cai
et al., 2011), formation of ROS (Schildknecht et al., 2011), MMP-
9 expression (Guo et al., 2011), and the delayed responses of
microglia (Yamada and Jinno, 2011). Its efﬁcacy has been tested
in Gunn rats, where it was shown to almost completely block
the loss of Purkinje and granule neurons, probably by inhibit-
ing p38 activation (Lin et al., 2005). Minocycline has a graded
neuroprotective capability in acute UCB neurotoxicity induced by
sulfadimethoxine in Gunn rat pups; while minocycline adminis-
tration 30min post-sulfadimethoxine totally prevented alterations
in BAEPs, the minocycline 120min post-sulfadimethoxine did not
FIGURE 10 | Shematic representation of some potential
neuroprotective, antioxidant, and anti-inflammatory adjunctive
therapies for preventing bilirubin-induced neurological dysfunction.
Given the marked oxidative stress, neuroinﬂammatory response, and cell
death elicited by unconjugated bilirubin (UCB) in neurons and glial cells, it
will be interesting to revise the potentialities of some particular
antioxidants and immunomodulatory agents such as the interleukin (IL)-10,
the bile acid glycoursodeoxycholic acid (GUDCA), and the antibiotic
minocycline. IL-10 revealed to reduce the UCB-induced release of
cytokines such as tumor necrosis factor (TNF)-α and IL-1β, as well as
nuclear factor-kappaB (NF-κB) activation and translocation to the nucleus.
In other conditions, IL-10 prevented apoptosis through the inhibition of the
cytochrome c (Cytc) release and of the caspase-3 cleavage, pointing to its
antiapoptic properties. Neuroprotective effects of the synthetic tetracycline
minocycline include: (i) cytoprotective, by decreasing glutamate and
excitotoxicity; (ii) anti-apoptotic, by reducing the release of Cytc and
therefore apoptosis; (iii) anti-inﬂammatory by decreasing the activity of the
metalloproteinase-9 (MMP-9), of caspase-1 or IL-1β converting enzyme
(ICE) and of NF-κB, and speciﬁcally directed to UCB immunostimulation by
preventing p38 phosphorylation, cytokine release, and cell death; (iv)
antioxidant by reducing reactive oxygen species (ROS) formation, as well
as nitric oxide synthase (NOS) expression and NO production. Concerning
GUDCA beneﬁts, it prevents the inﬂammatory effects of UCB by reducing
bothTNF-α and IL-1β release through the inhibition of TNF-α converting
enzyme (TACE) and ICE inhibition. GUDCA also prevented UCB-induced
energetic crisis by counter acting cytochrome c oxidase or complex IV
inhibition, oxygen consumption, extracellular ATP increase, intracellular
lactate, fructose-2,6-bisphosphate, oxidized glutathione (GSSG) increase,
protein oxidation, production of superoxide anion radical (O•−2 ) and NADPH
reduction, as well as necrosis and apoptosis by avoiding the collapse in the
mitochondrial transmembrane potential (ΔΨm) and caspase activity. Taken
together, minocycline and GUDCA may prove to have additional beneﬁts
over IL-10 in preserving neural cells functionality in cases of lasting
unconjugated hyperbilirubinemia, by abolishing and/or decreasing the
dangerous determinants of UCB brain injury, and reestablishing the
compromised ones, marked with stars. However, in what concerns
minocycline, applications in clinical settings dealing with pregnant women
and children are restricted and contentious.
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work anymore (Rice et al., 2011). In addition, it deserves to be
noticed that minocycline has several side effects such as gastroin-
testinal symptoms, pediatric tooth discoloration, and dizziness,
among many others (Smith and Leyden, 2005). Thus, applications
in clinical settings dealing with pregnant women and children are
restricted and contentious.
Ursodeoxycholic acid (UDCA) is an endogenous bile acid used
for the treatment of hepatobiliary disorders (Lazaridis et al., 2001).
Following oral administration, it is conjugated originating tau-
roursodeoxycholic acid and, mostly, glycoursodeoxycholic acid
(GUDCA), which acquires the highest clinical relevance (Rudolph
et al., 2002). Recent data indicate that unconjugated and conju-
gated UDCA species have anti-apoptotic, antioxidant, and anti-
inﬂammatory effects in nerve cells (Fernandes et al., 2007b; Solá
et al., 2007; Brito et al., 2008a), pointing to their therapeutic poten-
tial for CNS disorders (Parry et al., 2010; Fonseca et al., 2012).
UDCA has also shown to have beneﬁcial effects on itching and
in preventing liver failure in children with progressive familial
intrahepatic cholestasis (Davit-Spraul et al., 2010), as well as in
recovering liver function in patients with intrahepatic cholesta-
sis of pregnancy, a condition with fetal poor prognosis resulting
from increased transfer of bile acids from mother to fetus (Brites
et al., 1998c). In this disorder, UDCA is administered until labor,
decreasing the content of bile acids in the maternal serum, amni-
otic ﬂuid, cord blood serum, meconium and colostrum, improv-
ing fetal prognosis and showing to be safe for the mother and
babies (Brites and Rodrigues, 1998; Brites et al., 1998a,b; Brites,
2002). Thus,no secondary effects were observed in newborns from
UDCA-treated mothers, which showed a better liver function than
the non-treated babies (Mazzella et al., 2001). Interestingly,UDCA
has shown to decrease unconjugated hyperbilirubinemia in the
Gunn rat model, supporting its application in preventing BIND
(Cuperus et al., 2009).
In the neurotoxic effects produced by UCB in vitro, UDCA
revealed ability to prevent both necrosis and apoptosis in cultured
rat astrocytes and neurons (Figure 10; Silva et al., 2001b). Exper-
iments with GUDCA produced similar results in astrocytes (Fer-
nandes et al., 2007b). Interestingly, GUDCA also prevented the
UCB-induced release of TNF-α and IL-1β, but only reduced the
TNF-α mRNA induction. Curiously, it was observed that UCB
increases TACE and ICE activities, which were counteracted in the
presence of GUDCA, leading to the increase of the cytokine pro-
forms at the cytosol. Thus,whereas UCB promotes the maturation
of the cytokine pro-forms and their consequent release, GUDCA
inhibits their activation. Nevertheless, GUDCA did not modulate
either glutamate release or NF-κB activation. In addition, it was
observed that it prevents the decrease of GSH produced by UCB
in neurons together with the oxidation of proteins (Brito et al.,
2008a). GUDCA also completely precludes the inhibition of the
cytochrome c oxidase activity by UCB, the increase of the O•−2
production and the GSSG formation, as well as the decrease in
NADPH concentration and in oxygen consumption (Vaz et al.,
2010). The ability of GUDCA to prevent UCB-induced energetic
crisis and mitochondria dysfunction further supports the efﬁcacy
of this compound as a potential preventive therapy for BIND.
However, despite the beneﬁcial effects that UDCA may
have in early-life as a neuroprotectant, fundamental aspects of
investigation are still outstanding. Harnessing the potential of
UDCA for use in neonates clearly requires further investigation to
identify deﬁnitively the window of opportunity for UDCA inter-
vention once shortcoming in that most of the studies performed
have been by administration to the mother in the course of the
intrahepatic cholestasis of pregnancy.
IL-10 is another anti-inﬂammatory compound that was tested
in in vitro conditions mimicking BIND. It did not produce any
effect in both apoptotic and necrotic cell death of astrocytes,
neither in glutamate release (Fernandes et al., 2007b). In con-
trast, it prevented UCB-induced release of TNF-α and IL-1β by
down-regulating their expression, as well as abrogated NF-κB
translocation to the nucleus. In a recent study of spinal cord
injury it was used a herpes simplex virus-based vector to express
IL-10 in spinal cord in vivo (Zhou et al., 2009). In this case, the
cytokine was able to inhibit cytochrome c release and caspase-3
cleavage,pointing to the possibility that IL-10maypresent separate
effects from the anti-inﬂammatory properties. However, the anti-
apoptotic effectmay derive from the suppression of glial activation
as previously observed by Pang et al. (2005).
The aminoacid taurine is not only a neurotransmitter, but also
a trophic factor in CNS development. It maintains the structural
integrity of the membrane and regulates calcium transport and
homeostasis (Wu and Prentice, 2010). Taurine was initially indi-
cated to have beneﬁts in stroke together with anti-inﬂammatory
effects (Yamori et al., 2010; Sun et al., 2012). In 2010, taurine has
shown toprevent the loss of neuronal viability inducedbyUCB, the
changes in neurite outgrowth and the inﬂux of Ca2+from exter-
nal microenvironment, but with limited efﬁcacy on the release
of Ca2+ from ER (Zhang et al., 2010). Later, Gao et al. (2011)
observed the same properties in a jaundiced baby mice model
established by intraperitoneal injection with UCB. When these
mice were pretreated with taurine for 4 h, intracellular levels of
Ca2+ were inhibited and down regulation of caspase-3 activity
was achieved. Besides this anti-apoptotic effect, the new perspec-
tive for the use of taurine for preventing and/or treating neural
damage in neonatal jaundice comes from its anti-inﬂammatory
potential.
CONCLUSION
Although we have still a long way to envisage the complex and
diverse reactivity of astrocytes and microglia to UCB, and their
cross-talk with neurons in BIND conditions, in the present review
we attempted to provide information on how individual cell
response depends on the time of exposure to UCB, on the asso-
ciated stimuli and on the presence of each type of neural cell.
Receptor activation by UCB and signaling cascades followed by
injury due to lipid peroxidation and protein oxidation starts at the
cell membrane level. Targeted subcellular compartments by UCB
are ER, mitochondria and nucleus that orchestrate cell death by
apoptosis and necrosis. Alterations induced by UCB on neuro-
genesis, neuritogenesis, spinogenesis, and on axonal cytoskeleton
dynamics are suggestive of synaptic plasticity abnormalities and
lasting neurodevelopmental disabilities that should be further
investigated for their relevance andpriming effects. The extracellu-
lar increase in glutamate, in pro-oxidant factors, and the presence
of sepsis or inﬂammation that further enhances the susceptibility
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of neurons to UCB, even more in immature cells explain, at least
in part, the vulnerability of premature infants to BIND. How tem-
poral windows of neurodevelopment will inﬂuence and determine
increased brain damage by BIND and different type or sequelae at
early ages surely deserve additional studies, but preliminary data
suggest that infants in the ﬁrst postnatal week are more susceptible
to BIND than in the secondweek of life. UCB-induced reactivity of
microglia, although initially triggering a neuroprotective phagocy-
tosis of damaged neurons, decreasing their number but restricting
the area of damage, later it leads to the release of pro-inﬂammatory
mediators that activate TNF-α and IL-1β receptor signaling path-
ways in astrocytes, culminating in an additional production of
pro-inﬂammatory cytokinesmediated byMAPKs andNF-κB acti-
vation pathways. How far is the microglia reactivity modulated
by the other glial cells and neurons during unconjugated hyper-
bilirubinemia is just beginning to be studied. By interfering with
OPCs differentiation and proliferation, UCB can directly damage
myelinogenesis, although activated microglia can similarly pro-
duce the same effects, thus probably contributing to enhance the
damage of UCB to OPCs. Therefore, therapeutic strategies such
as GUDCA, IL-10, taurine, and minocycline directed at control-
ling the activation of microglia and astrocytes, and the excessive
production of pro-inﬂammatory and pro-oxidant factors, may be
valuable to control BIND and prevent long-lasting vulnerabilities
to elderly and adult neurodegenerative diseases resultant fromglial
sensitization or priming. Further studies using the organotypic
slice culture model will contribute to better identify risks, tar-
gets, and determinants of BIND and to improve our knowledge
on nerve cell pathological alterations as integrated phenomena. It
alsowill have an important role in the pharmacological assessment
of novel preventive and curative approaches, as well as strategies
based on new therapeutic indications. In closing, dysregulation of
“neurodevelopmental programming” by moderate and high levels
of UCB, enduring impacts on brain microglial function, and risk
for cognitive aging disorders warrant further research that should
lead to innovative treatments.
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